PatentJun 11, 2026, 09:02 AM
NeuroSense Granted South Korean Patent for PrimeC ALS Drug
AI Summary
NeuroSense Therapeutics Ltd. announced it has been granted a South Korean patent (No. 10-2969898) covering the composition of PrimeC, its lead drug candidate for Amyotrophic Lateral Sclerosis (ALS). The patent claims cover PrimeC's proprietary formulation, manufacturing process, and pharmaceutical use for ALS, providing protection in South Korea through 2042. This milestone expands NeuroSense's global intellectual property portfolio and supports its long-term development and commercialization strategy as the company prepares to initiate its pivotal Phase 3 PARAGON study for PrimeC.
Key Highlights
- NeuroSense granted South Korean Patent Number 10-2969898 for PrimeC composition for ALS.
- Patent claims cover PrimeC's proprietary tablet formulation, manufacturing process, and use in ALS.
- Patent protection in South Korea is expected to extend through 2042.
- This expands global intellectual property following grants in Japan, Brazil, Australia, and the US.
- Strengthens global patent portfolio as NeuroSense prepares for Phase 3 development of PrimeC.
- PrimeC previously showed compelling results in its Phase 2b PARADIGM study for ALS.
- FDA has cleared the pivotal Phase 3 PARAGON study in ALS, expected to enroll ~300 participants.
Price Impact
More from NRSN